Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Leuprolide Acetate (LHRH Analogue) Clear all
Not listed Phase 2 Interventional

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

NCT02689921
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Letrozole, Anastrozole, Leuprolide Acetate, Pertuzumab, Trastuzumab
Drug
Lead sponsor
Midwestern Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Newnan, Georgia • Zion, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 2, 2026, 3:20 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

GnRH Agonist at Embryo Transfer: IVF Outcomes

NCT03544073
View directory record Official record
Conditions
Infertility, Infertility, Female, Infertility, Male
Interventions
Saline Solution for Injection, Leuprolide Acetate
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 2, 2026, 3:20 PM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

NCT02064582
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Leuprolide acetate, radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 2, 2026, 3:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism With and Without Testosterone Replacement

NCT00001412
View directory record Official record
Conditions
Hypogonadism
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 3:20 PM EDT
Withdrawn Phase 4 Interventional

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

NCT00507780
View directory record Official record
Conditions
Ovarian Function, Preservation of Ovarian Function
Interventions
GnRH antagonist
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
10 Years to 21 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

NCT01088529
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone Acetate, Prednisone, LHRHa
Drug
Lead sponsor
Cougar Biotechnology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Not applicable Interventional

Leuprolide in Determining the Cause of Gonadotropin Deficiency

NCT00004426
View directory record Official record
Conditions
Hypogonadism
Interventions
gonadotropin releasing hormone, leuprolide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
9 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1998
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 2, 2026, 3:20 PM EDT
Terminated Phase 2 Interventional Results available

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

NCT01326312
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758 1000mg, Lupron Depot, GTx-758 2000mg
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
36
States / cities
Phoenix, Arizona • La Mesa, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 2, 2026, 3:20 PM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

NCT03298087
View directory record Official record
Conditions
Newly Diagnosed Oligometastatic Prostate Cancer
Interventions
radical prostatectomy, stereotactic body radiotherapy, Leuprolide, apalutamide, abiraterone
Procedure · Radiation · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Long Beach, California • West Los Angeles, California • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

NCT01546987
View directory record Official record
Conditions
Prostate Cancer
Interventions
GnRH agonist, Anti-androgen, TAK-700, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 136 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Terminated Phase 1 Interventional

Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer

NCT00512668
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Interventions
leuprolide acetate, goserelin acetate, bicalutamide, nilutamide, flutamide, temsirolimus, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Oct 2, 2026, 3:20 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

NCT07027124
View directory record Official record
Conditions
Prostate Cancer, High-risk Prostate Cancer
Interventions
Darolutamide, Pembrolizumab, Lupron
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hot Flashes on Sleep and Mood Disturbance

NCT01116401
View directory record Official record
Conditions
Menopause, Depression, Hot Flashes
Interventions
leuprolide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 2, 2026, 3:20 PM EDT
Recruiting No phase listed Observational

Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires

NCT05567198
View directory record Official record
Conditions
Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

NCT02058706
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Use of GnRH Agonist Trigger in the Prevention of OHSS

NCT00349258
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Leuprolide acetate
Drug
Lead sponsor
University of Connecticut
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2006 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 2 Interventional Results available

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

NCT00429494
View directory record Official record
Conditions
Amenorrhea, Premature Ovarian Failure, Ovarian Function Insufficiency
Interventions
Leuprolide Acetate, Questionnaire, Hematopoietic Stem Cell Transplantation
Drug · Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 40 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 2, 2026, 3:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Understanding Experimentally Induced Hot Flushes

NCT00455689
View directory record Official record
Conditions
Hot Flashes
Interventions
Leuprolide acetate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 2, 2026, 3:20 PM EDT
Recruiting Phase 2 Interventional

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

NCT05593497
View directory record Official record
Conditions
High-Risk Prostate Cancer
Interventions
Capivasertib, abiraterone acetate
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 2, 2026, 3:20 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Contributions to Hypertension With Androgen Deprivation Therapy

NCT05700903
View directory record Official record
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Interventions
Gonadotropin Releasing Hormone Agonists (GNRH), Androgen receptor (AR) inhibitor, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 2, 2026, 3:20 PM EDT